Brain metastases

Current Treatment Options in Neurology

Volumn 10, Issue 4, 2008, Pages 308-314

  Eichler, April F ^a   Plotkin, Scott R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIAZEPAM; ETIRACETAM; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LAMOTRIGINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PHENYTOIN; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMOZOLOMIDE; TOPIRAMATE; TOPOTECAN; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; ADRENAL INSUFFICIENCY; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANOREXIA; AVASCULAR NECROSIS; BEHAVIOR DISORDER; BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN METASTASIS; BRAIN RADIATION; BRAIN SURGERY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CATARACT; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CRANIOTOMY; CUSHINGOID SYNDROME; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; ENDOCRINE DISEASE; EXERCISE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GAIT DISORDER; GAMMA KNIFE RADIOSURGERY; HAIR LOSS; HAND FOOT SYNDROME; HOSPITAL COST; HUMAN; HYPERACTIVITY; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; INCONTINENCE; INDIGESTION; INSOMNIA; IRRITABILITY; KIDNEY TUBULE NECROSIS; LIVER TOXICITY; LUNG CANCER; MELANOMA; METASTASIS POTENTIAL; MOOD CHANGE; MYOPATHY; NAUSEA; NEUROTOXICITY; OPPORTUNISTIC INFECTION; OSTEOLYSIS; PEPTIC ULCER; PHYSIOTHERAPY; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; PSYCHOSIS; REVIEW; SALVAGE THERAPY; SEIZURE; SIDE EFFECT; SKIN IRRITATION; SOMNOLENCE; SPEECH THERAPY; STEREOTACTIC RADIOSURGERY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREMOR; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN;

EID: 58649106383     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0033-x     Document Type: Review

References (26)

1. Gavrilovic IE, Posner JB: Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005, 75:5-14.
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al.: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22:2865-2872.
3. Amer MH, Al-Sarraf M, Baker LH, et al.: Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival. Cancer 1978, 42:660-668.
4. Chang EL, Wefel JS, Maor MH, et al.: A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007, 60:277-283, discussion 283-274.
5. Mehta MP, Rodrigus P, Terhaard CH, et al.: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21:2529-2536.
6. Fife KM, Colman MH, Stevens GN, et al.: Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004, 22:1293-1300.
7. Lagerwaard FJ, Levendag PC, Nowak PJ, et al.: Identification of prognostic factors in patients with brain metastases: A review of 1292 patients. Int J Radiat Oncol Biol Phys 1999, 43:795-803.
8. Gaspar L, Scott C, Rotman M, et al.: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751.
9. Kaal EC, Niel CG, Vecht CJ: Therapeutic management of brain metastasis. Lancet Neurol 2005, 4:289-298.
10. Patchell RA, Tibbs PA, Walsh JW, et al.: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
11. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al.: Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann Neurol 1993, 33:583-590.
12. Barker FG 2nd: Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: Decreasing mortality and the effect of provider caseload. Cancer 2004, 100:999-1007.
13. Borgelt B, Gelber R, Larson M, et al.: Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981, 7:1633-1638.
14. Patchell RA, Tibbs PA, Regine WF, et al.: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998, 280:1485-1489.
15. Andrews DW, Scott CB, Sperduto PW, et al.: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
16. Rutigliano MJ, Lunsford LD, Kondziolka D, et al.: The cost effectiveness of stereotactic radiosurgery versus surgical resection in the treatment of solitary metastatic brain tumors. Neurosurgery 1995, 37:445-453, discussion 453-455.
17. Glantz MJ, Cole BF, Forsyth PA, et al.: Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
18. Rivera E, Meyers C, Groves M, et al.: Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006, 107:1348-1354.
19. Lassman AB, Abrey LE, Shah GD, et al.: Systemic highdose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006, 78:255-260.
20. Abrey LE, Olson JD, Raizer JJ, et al.: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001, 53:259-265.
21. Christodoulou C, Bafaloukos D, Kosmidis P, et al.: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001, 12:249-254.
22. Dziadziuszko R, Ardizzoni A, Postmus PE, et al.: Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003, 39:1271-1276.
23. Giorgio CG, Giuffrida D, Pappalardo A, et al.: Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 2005, 50:247-254.
24. Omuro AM, Raizer JJ, Demopoulos A, et al.: Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: A phase I trial. J Neurooncol 2006, 78:277-280.
25. Lin NU, Carey LA, Liu MC, et al.: Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer [abstract 503]. J Clin Oncol ASCO Annual Meeting Proceedings 2006, 24(June 20 Suppl).
26. Shimato S, Mitsudomi T, Kosaka T, et al.: EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib. Neuro Oncol 2006, 8:137-144.